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Key Points
• We demonstrated that patients with non-organic chronic constipation regard the symptom of bloating as a key
element in assessing clinical changes and treatments’ efficacy irrespective of the intensity of other symptoms
• We sought to evaluate the association between bloating and quality of life, treatment satisfaction and treatment
responsiveness among patients with constipation-predominant irritable bowel syndrome and functional
constipation.
• We enrolled 2203 patients in a two-wave cross-sectional survey: quality of life data obtained through self-
administered questionnaires were matched with reports of clinical examinations performed by gastroenterol-
ogists in 39 tertiary referral centers for the treatment of non-organic constipation.
• Bloating was associated with poorer health-related quality of life and treatment satisfaction after adjustment for
potential confounders and other constipation-related symptoms.
• Bloating was associated with responsiveness to treatment after therapy switch independent of potential
confounders.
Abstract
Background The management of bloating is unclear
and its relationship with patients’ well-being and
treatment satisfaction independent of other abdomi-
nal symptoms is uncharacterized. We evaluated the
association of bloating with patient-reported out-
comes. Methods Thirty-nine centers for functional
gastrointestinal disorders joined the laxative inade-
quate relief survey. We enrolled 2203 consecutive
outpatients with functional constipation (FC) or
constipation-predominant irritable bowel syndrome
(IBS-C) in two cross-sectional waves. Both wave 1 and
2 included the SF-12, the patient assessment of
constipation-symptoms (PAC-SYM), and the treat-
ment satisfaction questionnaire for medication
(TSQM-2). Wave 2 only included a global rating of
change (GRC) scale to assess patients’ assessment of
efficacy concerning treatment switches occurred in the
3 months prior to the interview. Bloating in the
abdomen was defined on the basis of PAC-SYM item
3. Key Results The average age was 50.1 years (SD,
16.7) and 82.1% of patients were women. The preva-
lence of bloating was 91.6% (n = 1970). Bloating was
associated with SF-12 Physical Composite Score
(p < 0.01), SF-12 Mental Composite Score (p < 0.01),
GRC (p < 0.01), Satisfaction with treatment effective-
ness (p < 0.01), convenience of administration
(p < 0.01), and side effects (p < 0.01) after adjustment
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for possible confounders. Conclusions & Inferences
Our data suggest that patients regard bloating as a key
element in assessing clinical changes and treatments’
efficacy as this symptom exerts a strong influence on
patient-reported outcomes independent of possible
confounders and other symptoms of constipation. Our
data provide the rationale to investigate the efficacy
and tolerability of new treatments specifically address-
ing this important, yet disregarded, patients’ complain.
Keywords bloating, chronic constipation, functional
constipation, irritable bowel syndrome, patient-
reported outcomes, quality of life, treatment satisfac-
tion.
Abbreviations: FC, functional constipation; FGID,
functional gastrointestinal disorder; GRC, global rating
of change; IBS – C, constipation-predominant irritable
bowel syndrome; LIRS, laxative inadequate relief sur-
vey; PAC-SYM, patient assessment of constipation-
symptoms; PRO, patients-reported outcomes; QoL,
quality of life; TSQM-v2, treatment satisfaction ques-
tionnaire for medication.
BACKGROUND
Bloating is one of the most common and bothersome
complaint in the general population.1 This symptom
has been described with various definitions, such as
sensation of a distended abdomen or an abdominal
tension or even excessive gas in the abdomen, although
bloating should probably be defined as the feeling (e.g.,
a subjective sensation) of increased pressure within the
abdomen.2 Additionally, it is not clear to what extent
patients’ complaint of subjective bloating corresponds
to the objective evidence of abdominal distension.3
Bloating is frequently associated with functional
gastrointestinal disorders (FGIDs) (i.e., functional
dyspepsia, irritable bowel syndrome [IBS], and func-
tional constipation [FC]). Up to 80% of patients with
constipation complain of bloating and abdominal dis-
tension,4–9 whereas 96% of patients with IBS report
bloating, which is considered the most bothersome
symptoms in 60% of them.7
There is evidence documenting a weak association
between bloating and quality of life (QoL)10,11 but no
study comprehensively addressed the relationship of
this common symptom with patients well-being and
treatment satisfaction independent of other lower
abdominal complains. Additionally, to our knowledge,
no study has evaluated whether constipated patients
are less responsive to constipation-related treatments
in the presence of bloating.
Hence, we sought to assess the association of
bloating with QoL and treatment satisfaction in
patients with FC and IBS.
METHODS
Study sample and design
Thirty-nine Italian referral centers for gastrointestinal disorders
joined the laxative inadequate relief study (LIRS),12 a two-wave
survey. In the first wave, LIRS 1, we enrolled 878 consecutive
outpatients with chronic non-organic constipation from Septem-
ber through December 2011. In the second wave, LIRS 2, we
enrolled 1325 outpatients in the same centers, from March 2012
and May 2013. Patients reporting at least two symptoms of FC
according to Rome III criteria were evaluated by a gastroenterol-
ogist. The attending gastroenterologist recorded relevant clinical
and demographic information in a standard data collection form.
All participating gastroenterologists were experienced in the
diagnosis and treatment of FGIDs and were instructed to exclude
patients with secondary causes of constipation. Patients were
classified in the FC or constipation-predominant IBS-C group,
based on criteria listed in Table 1.
Patients willing to participate in the study and providing their
informed consent were asked to fill in a self-administered survey.
We matched the medical data collection form and the self-
administered questionnaire for all study subjects.
Measures
Outcomes (see also Appendix S1) We assessed patients’ health-
related QoL with the SF-12,13 the severity of constipation with the
patient assessment of constipation-symptoms (PAC-SYM),14 and
treatment satisfaction with the treatment satisfaction question-
naire for medication (TSQM-v2).15
The PAC-SYM is a 12-item questionnaire assessing the
presence and magnitude of constipation-related symptoms
worded as follows: (1) discomfort in your abdomen; (2) pain in
Table 1 Classification of FC and IBS-C according to modified ROME
III definition
Functional constipation
At least two of the following
symptoms for the last 3 months
with symptom onset at least
6 months prior to diagnosis
Lumpy/Hard Stools in at least
25% of defecations
Feeling of incomplete evacuation
in at least 25% of defecations
Sensation of anorectal
obstruction/blockage for at
least 25% of defecations
Manual maneuvers to facilitate
at least 25% of defecations
Less than 3 defecations/week
Straining during at least 25% of
defecations
IBS-C
All criteria should be satisfied
Fulfilling criteria for functional
constipation
Abdominal Pain or discomfort
lasting at least 3 days/month in
the past 3 months associated
with relief of pain with a bowel
movement
Abdominal pain is the most
bothersome symptom
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your abdomen; (3) bloating in your abdomen; (4) stomach cramps;
(5) painful bowel movements; (6) rectal burning during or after a
bowel movement; (7) rectal tearing or bleeding after a bowel
movement; (8) incomplete bowel movement, like you didn’t
‘finish’; (9) bowel movements that were too hard; (10) bowel
movements that were too small; (11) straining or squeezing to try
to pass bowel movements; (12) feeling like you had to pass a bowel
movement you couldn’t. Ratings occur along a 5-point likert scale
(0 = absent; 4 = very severe). Items of the PAC-SYM question-
naire were identified through literature review and qualitative
analysis of patient interviews (five focus groups of 8–10 patients
per group, separated by sex and by two levels of self-reported
constipation severity). Of note, to maximize the relevance of the
symptom assessment to patients, items were constructed from
the symptom description language used by focus-group patients. A
recall period of 2 weeks was chosen for items to limit recall
burden and to provide a relatively acute assessment. The instru-
ment was designed for self-administration. Five pilot subjects
completed the questionnaire to evaluate comprehensiveness and
understandability. Furthermore, standard item reduction tech-
niques were employed to select relevant items.14
The SF-12 is a 12-item questionnaire assessing patients’ percep-
tion of their own mental and physical health. Response to the
questionnaire yield two composite scores (the Mental Composite,
MCS and the Physical Composite, PCS) ranging from 0 to 100, with
higher scores indicating better QoL. The scoring system is norm
based on the Italian general population (mean = 50; SD = 10).
The TSQM-v2 is an 11-item questionnaire assessing patients’
satisfaction for the efficacy, safety, and convenience of use of their
treatment. Patients response yield three subscales (efficacy,
safety, and convenience) and an overall satisfaction rating. Scores
occur on a 0–100 scale. Higher ratings indicate higher satisfaction
with medication.
The LIRS II survey additionally inquired about therapy switching
in the3 monthsprior to the interview.Weaskedpatients to rate their
perceived overall clinical change after therapy switch with a bipolar
GlobalRating ofChange Scale (GRC, 15 point, from7 = extremely
deteriorated to +7 = extremely improved).16 As it has been previ-
ously suggested that theMinimal Clinically Important Change on a
GRC scale is 2 points,16 we classified patients ratings of clinical
changeas follows:7 : 5 = verydeteriorated;4 :2:deteriorated;
1 : 1 = unchanged; +2 : +4 = improved; +5 : +7 = very improved.
Definition of bloating Item 3 of the PAC-SYM was used to define
patients with (score = 1–4) and without bloating (score = 0).
Covariates The covariates included in the model were patients’
age, sex, employment, the diagnosis of IBS-C or FC based on
ROME III criteria and the presence of abdominal pain and its
characteristics, BMI, smoking habit, daily intake of water greater
than 1 L (yes/no), duration of lower gastrointestinal symptoms
(years since diagnosis), number of pregnancies and difficult
deliveries, and the number of comorbidities and treatments
(behavioral advice, bulking/osmotic, stimulant/herbal, enema/
suppository, prucalopride, any association, or no therapy). Comor-
bidities included all diseases treated or diagnosed in the past
12 months and previous abdominal and extra-abdominal surgical
interventions occurred in the same time frame as well.
Analysis
We defined questionnaire completers as all patients with no
missing value in items relevant for questionnaire scoring. For
each questionnaire item, the prevalence of missing values ranged
from 1% to 7%. We tested differences in socio-demographic and
clinical factors (see Measures, Covariates) among completers and
non-completers with chi-squared and Wilcoxon test where appro-
priate. As we found no statistically significant differences
between completers and non-completers in both LIRS I and LIRS
II waves, we computed all questionnaire scores only for cases with
complete answers.
Prevalence and magnitude of bloating The prevalence (PAC-
SYM item 3 ≥ 1) and magnitude (PAC-SYM item 3 score) of
bloating have been computed in patients with FC and IBS-C. We
evaluated unadjusted differences in the prevalence and magnitude
of bloating with chi-squared and Wilcoxon test. We adopted
logistic regression and generalized linear models to evaluate
correlates of the prevalence and magnitude of bloating,
respectively.
Bloating and patient-reported outcomes To test whether bloating
was associated with poorer patient-reported outcomes (PRO), we
used Wilcoxon test to contrast QOL (SF12 summary scores),
Treatment Satisfaction (TSQMv2 scales), and GRC scores
between patients with and without bloating. We adopted gener-
alized linear models to test the robustness of the results after
adjustment for possible confounders and overlap-corrected PAC-
SYM score (total score after deletion of the score reported in Item
3, the descriptor of bloating).
Sensitivity analysis Even though we advised all participating
gastroenterologists to exclude any patient with alarm signs and
any organic disease potentially associated with constipation, we
relied on each center clinical practice rather than providing a
standardized diagnostic algorithm for the study. As a conse-
quence, a bias in patient enrollment cannot be completely ruled
out. To evaluate the potential impact of selection bias we
assessed differences in bloating prevalence, constipation charac-
teristics (Rome III criteria), socio-demographic, and clinical
characteristics between patients with and without organic
diseases potentially associated with constipation (i.e., diabetes,
anal fissures, previous history of abdominal surgery, clinical
depression, chronic kidney disease, endometriosis, suspect heavy
metals intoxication, cancers and neoplasms, hysterectomy,
Alzheimer’s disease or dementia, Parkinson’s disease, multiple
sclerosis, paraplegia or hemiparesis, diverticulosis, rectal
prolapse; n = 654).
As a further check, we included the interaction term between
bloating and an indicator variable denoting a medical history
suggesting organic diseases potentially associated with constipa-
tion in all models evaluating the association between bloating and
PRO (SF-12, TSQMv2, overlap-corrected PAC-SYM). A statisti-
cally significant interaction term would suggest possible selection
bias. This procedure allows to estimate both the magnitude and
the direction of possible selection bias. We report the difference-
in-difference of the adjusted means calculated as follows:
Dps ¼ ðaMeanb1  aMeanb0Þp  ðaMeanb1  aMeanb0Þs
where aMeanb1 indicate the adjusted mean for patients reporting
bloating; aMeanb0 indicate the adjusted mean for patients report-
ing no bloating. The suffix p indicates the group of patients with
no previous history of organic diseases potentially associated with
constipation. The suffix s indicates the group of patients with
previous history organic diseases potentially associated with
constipation. A statistically significant interaction and a positive
Dp-s would suggest that the inclusion of patients with organic
diseases potentially associated with constipation may lead to
underestimating the association between bloating and PRO.
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A p < 0.05 was considered statistically significant. We carried




Patients’ characteristics are described in Table 2. LIRS
1 and LIRS 2 were substantially similar relative to key
patients’ characteristics. About 55% (n = 1212)
received dietary prescriptions alone or in associations
with other treatments. Additionally, 512 patients
(23.2%) received fiber supplementation alone or in
associations with other treatments. There was no
difference across bloating groups in the proportion of
patients receiving dietary prescriptions or fiber supple-
mentation (data not shown). Most patients received
associations of constipation-related treatments in the
month prior to the interview (i.e., schemes including a
combination of more than one drug with or without
dietary recommendation). Overall patients receiving
dietary recommendations or fiber supplementation
alone or in association with other treatments were
208 (12.7%) and there was no difference in the
proportion of fiber supplementation prescription across
bloating strata. During LIRS I, fielding prucalopride
was not available in Italy. During LIRS II, 151 (11.4%)
patients received a prescription for prucalopride alone
and 167 (12.6%) patients in association with other
treatments. Most common prucalopride associations
were dietary (16.4%), bulking/osmotic (14.8%), enema/
suppository (13.5%), and stimulant/herbal (7.9%) treat-
ments. Prescription of prucalopride was a switch from
previous treatments in the majority of patients (94%).
Mean overlap-corrected PAC-SYM score (i.e., total
score after deletion of the score reported in Item 3,
the PAC-SYM descriptor of bloating) was 1.46  0.77.
Prevalence and magnitude of bloating
The prevalence of bloating was 91.6% (n = 1970).
Patients with IBS-C reported slightly more bloating
than patients with FC (95.9%, n = 347 vs 90.8%,
n = 1623 in IBS-C and FC, respectively; p < 0.01). After
adjustment for possible confounders (covariates in the
methods section), IBS-C (OR = 2.80, p < 0.01), women
(OR = 2.36, p < 0.01), obese subjects (BMI >30)
(OR = 3.51, p < 0.01) and patients with more comor-
bidities (>3: OR = 2.04; 1–3: OR = 1.96; 0: ref.;
p < 0.01) were more likely to report any bloating. The
magnitude of bloating (PAC-SYM item 3) was greater
in patients with IBS-C compared to FC (2.69  0.93 vs
2.38  0.98, p < 0.01, respectively). After adjustment
for possible confounders, patients with a diagnosis of
IBS-C (b = 0.32, p < 0.01), women (b = 0.56, p < 0.01),
those with a paid job (b = 0.15, p < 0.01), older subjects
(less than 33 years: reference; 33–67 years: b = 0,14;
older than 67 years: 0.34; p < 0,01), those currently
smoking (b = 0.14, p < 0.01), and those with more
comorbidities (0 medical conditions: b = 0.59; 1–3
medical conditions: b = 0.20; >3 medical conditions:
reference; p < 0.01) reported higher bloating magni-
tude. A diagnosis or treatment for depression/anxiety
in the past 12 months (b = 0.12, p < 0.053) was
marginally associated with bloating magnitude.
Bloating and quality of life
Patients with bloating reported lower QOL scores
independently of the diagnosis of FC or IBS-C (Fig. 1,
Panel A). Additionally, we observed that the relation-
ship between bloating and HRQOL was not different in
patients with FC or IBS-C (p for interaction >0.1). This
pattern of association was robust to adjustment for
Table 2 Characteristics of sample study
Characteristics Whole sample LIRS I LIRS II
n 2203 878 1325
Mean (SD), n (%)
Age 50.1 (16.7) 50.3 (16.6) 49.9 (16.9)
Women 1808 (82.1) 706 (80.4) 1102 (83.2)
Employed 1090 (49.5) 370 (42.1) 720 (54.3)
IBS-C 369 (16.8) 149 (17.0) 220 (16.6)
FC 1834 (83.3) 729 (83.0) 1105 (83.4)
Rome III criteria
Lumpy/Hard stools 1638 (74.4) 659 (75.1) 979 (73.9)
Incomplete evacuation 1604 (72.8) 650 (74.0) 954 (72.1)
Sensation of obstruction 346 (40.4) 346 (40.4) 507 (38.3)
Manual maneuvers 539 (24.5) 220 (25.1) 319 (24.1)
<3 defecations/week 1501 (68.2) 565 (64.4) 936 (70.7)
Straining 1812 (82.3) 723 (82.4) 1089 (82.3)
Bloating prevalence 1970 (91.6) 778 (92.4) 1192 (91.1)
Time since constipation
onset
11.9 (13.7) 17.3 (15.0) 7.0 (10.2)
Therapy (mutually exclusive classes)*
Behavioral advice 266 (12.2) 125 (14.6) 141 (10.7)
Bulking/osmotic 157 (7.2) 43 (5.0) 114 (8.6)
Stimulant/herbal 113 (5.2) 52 (6.1) 61 (4.6)
Enema 58 (2.7) 23 (2.7) 35 (2.6)
Prucalopride – N/A 151 (11.4)
Any association† 1352 (62.0) 563 (65.7) 789 (59.6)
None 107 (4.9) 51 (5.9) 56 (4.2)
Water >1 L/day 1325 (60.3) 537 (61.7) 788 (59.5)
Current smoker (Y) 806 (36.6) 325 (38.1) 477 (36.0)
Number of comorbidities 2.4 (2.0) 2.5 (2.1) 2.3 (1.9)
BMI 23.6 (4.1) 23.8 (4.0) 23.5 (4.3)
Cesarean birth or
prolonged labor‡
605 (33.5) 224 (31.7) 381 (34.6)
*Missing information concerning treatment: n = 150. †Any Associa-
tion entails a combination of multiple treatments. ‡Statistics based on
1808 women.
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possible confounders (Table 3). The association
between bloating and SF-12 physical composite (Bloat-
ing: b = 2.34, p < 0.01) was independent of other
constipation-related symptoms (overlap-corrected
PAC-SYM scores: b = 3.83, p < 0.01). On the contrary
the association between bloating and SF-12 mental
composite (Bloating: b = 0.64, p = 0.46) was not inde-
pendent of other constipation-related symptoms (over-
lap-corrected PAC-SYM score: b = 4.69, p < 0.01).
Bloating and treatment satisfaction
Among patients without bloating, 78% (n = 112)
reported to be partially or completely satisfied with
the effectiveness, 96% (n = 136) with the safety and
91% (n = 127) with the convenience of administration
of their treatment. Patients with bloating reported
lower satisfaction on all dimensions (59%, 87%, and
82% respectively, p < 0.01). Additionally, patients
with bloating reported lower treatment satisfaction
scores independent of the diagnosis of FC or IBS-C
(Fig. 1, Panel B). Bloating was associated with treat-
ment satisfaction independent of possible confounders
(Table 3). After adjustment for overlap-corrected PAC-
SYM scores, bloating was still associated with TSQM
Effectiveness (b = 4.79, p < 0.01) and TSQM Conve-
nience (b = 4.63, p = 0.02), while the association
with TSQM Safety was strongly attenuated and lost
statistical significance (b = 2.82, p = 0.23).
Bloating and clinical change after therapy switch
A minority (n = 413, 30%) of LIRS II patients initiated
a new therapy in the 3 months prior to the interview.
Most patients (66%) reported subjective clinical
improvement after switch or initiation of therapy,
27% reported no clinical change and only 7% reported
worsening symptoms. Bloating was strongly associated
with patients’ rating of change after therapy switch
independent of treatment and adjustment for possible
confounders (Table 4).
Sensitivity analysis
Patients with a medical history of conditions possibly
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Figure 1 Bloating, quality of life, and treatment satisfaction. Association between bloating SF-12 (A) and TSQMv2 (B) scores based on estimated
scores from general linear models. Higher scores indicate higher quality of life (A) or patients’ satisfaction with medications (B). The model included
an indicator variable denoting the presence/absence of bloating and the diagnosis of IBS-C/FC. The interaction term between bloating and diagnosis of
IBS-C/FC was not statistically significant.
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(56.7 vs 47.4, p = 0.02) and more likely to report a
feeling of incomplete evacuation in at least 25% of
defecations (78% vs 71%, p < 0.05), a sensation
of anorectal obstruction/blockage for at least 25% of
defecations (48% vs 36%, p < 0.05), the need to adopt
manual maneuvers to facilitate at least 25% of defe-
cations (22% vs 30%, p < 0.05). We observed no
differences in bloating prevalence, IBS prevalence,
gender, fluid intake >1 L/day, smoking habit, treat-
ment, time since constipation onset across patients
with/without previous history of organic diseases
potentially associated with constipation (data not
shown). The relationship between bloating and
health-related QoL (SF-12) was not moderated by the
inclusion/exclusion of patients with medical history of
conditions possibly associated with secondary consti-
pation (SF-12, PCS: p for interaction = 0.79; SF-12,
MCS: p for interaction = 0.20). On the contrary, mod-
eration analysis revealed that the association between
bloating, treatment satisfaction, and other constipa-
tion-related symptoms was weaker in patients with a
medical history of conditions possibly associated with
secondary constipation. As such, the inclusion of
patients with organic constipation in the analysis
may lead to underestimating the association between
patients’ report of bloating and constipation severity
(overlap-corrected PAC-SYM: Dp-s = 0.49, p < 0.01),
satisfaction with treatment effectiveness (TSQMv2-
Effectiveness: Dp-s = 12.38, p < 0.01), and satisfaction
with treatment convenience of administration
(TSQMv2-Convenience: Dp-s = 14.39, p < 0.01).
DISCUSSION
In this large cross-sectional study, we observed a strong
association between bloating, health-related QoL, and
treatment satisfaction independent of the diagnosis of
IBS-C or FC, other constipation-related symptoms and
possible confounders. Finally, we found that patients
with bloating were less responsive to treatment and
that the intensity of bloating was strongly related to
the subjective clinical rating of change after therapy
switch.
Given its widespread prevalence, bloating has been
considered a supportive symptom rather than part of
the diagnostic criteria for most FGIDs so far; however,
when bloating is not part of another functional bowel
or gastrointestinal disorder it is classified as an
Table 3 Correlates of patient-reported outcomes
PAC-SYM† SF-12: PCS SF-12: MCS Effectiveness Side effects Convenience
Characteristics Unstandardized regression coefficient estimates
Intercept 1.17 52.71 42.61 65.71 85.15 76.40
Bloating 0.59** 4.71** 3.54** 11.53** 9.21** 10.15**
IBS-C (reference: FC) 0.19** 1.07* 1.40** 1.29 1.40** 0.41
Age‡ 0.06** 1.01** 0.07 0.28 1.28* 0.51
Women 0.09 0.60 1.42* 0.44 0.60 2.15
Employed 0.06 2.10** 0.96 1.56 4.39** 2.62*
Time since disease onset§ 0.04* 0.11 0.005 0.41 0.49 0.24
Current smoker (Y) 0.02 0.30 0.78 1.05 0.43 0.69
Water >1 L/day 0.01 0.17 0.40 0.41 0.06 1.73
Number of comorbidities 0.08** 1.09** 0.90** 0.94** 2.00** 0.41
BMI¶ 0.02 0.47 0.20 0.65 0.34 0.10
Diabetes 0.01 1.14 0.96 1.07 2.46 3.69
Depression/anxiety 0.05 0.47 5.94** 1.74 3.47 1.77
Therapy
Diet/other 0.53** 1.49 1.14 18.33** 7.46** 16.44**
Bulking/osmotic 0.64** 1.52 3.49** 13.14** 3.27** 17.99**
Stimulant/herbal 0.78** 1.25 2.34 17.70** 8.33** 18.80**
Enema 0.68** 2.01 1.72 16.80** 7.31** 22.26**
Any association 0.63** 2.25** 2.79** 16.19** 7.00** 18.91**
None 0.62** 0.65 1.16 25.57** 21.90** 23.46**
Prucalopride Reference Reference Reference Reference Reference Reference
Unstandardized regression coefficient estimates represent the change in the dependent variable for a 1-unit change in the independent variable. For
categorical variables (e.g., presence/absence of bloating), the parameter represent the change in the dependent variable when the condition is present.
The intercept estimates represent the baseline value of the dependent variable when all covariates in the model are set to their reference category (i.e.,
patients reporting no bloating, men, with FC, 18 years old, unemployed, with a first diagnosis of chronic non-organic constipation in the past month,
non-smoking, with BMI = 23.6, with no comorbidities and treated with prucalopride). Comparisons across treatment groups are contrasted against
the reference group ‘prucalopride’: hence, each parameter estimate represents the change in score occurring with a treatment option compared to the
reference category after adjustment for covariates and confounders. Higher scores of the SF-12 and TSQM II questionnaire represent higher quality of
life and treatment satisfaction, respectively. †PAC-SYM score corrected for overlap; ‡10-year intervals; §5-year intervals; ¶5-unit intervals; *p < 0.05;
**p < 0.01.
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independent entity named functional bloating17 by the
Rome III consensus. In our sample bloating was more
prevalent in women, obese subjects and those with IBS-
C. Even though the odds ratios for these factors
indicated a strong association, bloating prevalence in
men without these conditions was still very high. Our
sensitivity analysis further showed that inclusion of
patients with any organic disease potentially associ-
ated with constipation had little impact on the preva-
lence estimates of bloating. Taken together, these
results suggest that bloating is a widespread problem in
all patients with constipation independent of their
clinical diagnosis.
A key finding of our study was that bloating was
associated with reduced physical functioning (SF12-
Physical Composite Score) independent of possible
confounders (including abdominal pain and diagnosis
of FC/IBS-C). This difference approached clinical
significance according to common minimal clinically
important difference standards for QoL measures18
indicating that the difference observed may be appre-
ciated by patients as a real difference in QoL. This
finding is in contrast with previous reports showing
that only abdominal pain and diarrhea, but not bloating
and other IBS-related symptoms, were independently
associated with reduced QoL.10 One difficulty in
assessing the association of bloating and QoL indepen-
dent of abdominal pain in previous studies might be
that such symptoms are strongly related. Our large
sample size allowed greater precision and extensive
adjustment, thus reducing confounding bias.
Paired with HRQOL data, we observed greater
treatment satisfaction in patients without bloating
after adjustment for other constipation-related symp-
toms. Consistent with our observation, relief from
bloating was the most difficult endpoint to achieve for
all common therapies, in a recent European survey.19
A further important finding of our study was that
patients with bloating were less responsive to various
constipation-related treatments independent of socio-
demographic factors, general health, therapy, and the
diagnosis of IBS-C or FC. Overall, this evidence
suggests that bloating might be a relevant independent
target of therapy despite it currently remains without a
proper clinical classification, a clear pathophysiology,
and an effective treatment. Our study highlights the
importance of bloating as an independent clinical
feature in patients with FC and IBS-C. In theory, a
pharmaceutical agent that can stimulate intestinal gas
flow might have beneficial effects on this symptom.
There is experimental evidence that prokinetic drugs
such as 5-HT4 receptor agonists could effectively
address bloating.20–28 Additionally, patients treated
with linaclotide, a minimally absorbed 14 amino acid
peptide enhancing luminal fluid secretion and bowel
motility, reported improvements of bloating sensations
during a 12-week follow-up randomized controlled
parallel group clinical trial against placebo.29 However,
the sensation of abdominal distension is often reported
by patients with somatization disorders, a condition
associated with a propensity to amplify the intensity
and significance of bodily sensations, which in turn
may be associated with greater healthcare-seeking
behavior,30 reduced treatment satisfaction, and worse
responsiveness to treatment of somatic symptoms.
Our study was not designed to shed light on the
pathophysiological mechanisms underlying bloating,
other lower GI symptoms, and PRO. Hopefully, further
research would evaluate the inter-play between abdom-
inal distension, sensation of bloating, and other
constipation-related symptoms thus helping to manage
these difficult patients.
Our study has several strengths. Firstly, we were
able to provide a comprehensive picture of PRO (i.e.,
QoL, treatment satisfaction and clinical rating of
change after therapy) thus allowing to inspect patients’
perspective concerning bloating burden on several
Table 4 Correlates of global rating of change after therapy switch
Model 1 Model 2 Model 3
Unstandardized regression coefficient estimates
Intercept 3.34 4.52 6.61
Bloating 1.15** 1.48** 0.64
IBS-C – 0.09 0.03
Women – 0.40 0.77
Unemployed – 0.29 0.37
Non-smoker – 0.17 0.26
Diabetes – 0.65 0.23
Depression – 0.28 0.60
Fluid intake <1 L – 0.45 0.22
Time since symptoms onset – 0.01 0.01
Number of comorbidities – 0.37** 0.31**
BMI – 0.02 0.01
PAC-SYM (overlap corrected) – – 1.38**
Treatment after switch
Prucalopride – monotherapy Ref. Ref. Ref.
Other monotherapies* 1.15** 1.28** 0.56
Prucalopride – associations 0.84** 0.69 0.55
Other associations 1.46** 1.30** 0.58
General linear models. Variables included in Model 1: bloating,
treatment after switch; Model 2: Model 1+ IBS-Like pain, gender,
employment, smoke, diabetes, depression, fluid intake, time since
disease onset, number of comorbidities, BMI; Model 3: Model 2+
Overlap corrected Pac-Sym score. *Monotherapies include dietary
prescription, bulking/osmotics, herbal/stimulants, enema/suppository
alone. Unstandardized regression coefficient estimates represent the
change in the dependent variable for a 1-unit change in the indepen-
dent variable. For categorical variables (e.g., presence/absence of
bloating), the parameter represent the change in the dependent variable
when the condition is present.
**denotes statistically significant associations at P < 0.05.
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dimensions of well-being and health. Secondly, our
large sample size and extensive data collection allowed
adjustment for potentially important confounders.
Thirdly, clinical data and patients’ screening for
inclusion was conducted by expert gastroenterologists
thus reducing information and classification bias.
Additionally, our sensitivity analysis showed that the
association between bloating and PRO was stronger in
patients with FC or IBS-C compared to subjects with
medical conditions associated with secondary
constipation. Thus, including patients with secondary
constipation in the sample might lead to underesti-
mating the association between bloating and PRO.
Finally, the association of bloating on PRO observed in
the cross-sectional analysis was confirmed in the
longitudinal section of our study.
Nevertheless, we should acknowledge some limi-
tations. Firstly, observational studies cannot prove
causality as residual confounding by unmeasured
variable can never be completely ruled out. Secondly,
even though a gastroenterologist compiled a stan-
dardized form on patients’ clinical characteristics, we
lacked information on physiological tests of bowel
function, which may have helped classify patients in
functional sub-types. Thirdly, patients included in
our study were referred to a 3rd level center and our
findings may not be generalizable to all patients with
FC or IBS-C. It should be noted however that the
average PAC-SYM score in our sample was as low as
that reported in the PAC-SYM validation study, a
research which recruited patients from the general
population by advertisement.14 Overall our results
support the internal validity of our study. Prevalence
estimates and risk factors for bloating are consistent
with several previous reports in the same source
population thus reducing the likelihood of selection
bias and information bias.7 Fourthly, we lacked
detailed information allowing us differentiating
between subjective bloating and objective abdominal
distension, thus limiting our ability to further inspect
the differential impact of these distinct conditions on
PRO. Finally, we could not collect detailed dietary
information in this study. Fermentable oligosaccha-
ride, disaccharide, monosaccharide, and polyol (FOD-
MAP)-restricted diet have recently shown promising
outcomes in the management of FC and IBS-C.31
Additionally, dietary intake of alimentary
fibers might be associated with increased bloating.32
As a consequence we could not evaluate the impact
of different diets on bloating prevalence and
magnitude.
In conclusion, we found that bloating is a highly
prevalent and bothersome symptom which is partially
independent of other lower gastrointestinal complaints
in patients’ with FC and IBS-C. Our data suggest that
patients regard bloating as a key element in assessing
treatments’ efficacy as this symptom exerts a strong
influence on QoL independent of other constipation-
related symptoms. Paired with its prevalence among
constipated patients and the lack of established
management options, our data provide the rationale
to investigate the efficacy and tolerability of new
treatments specifically addressing this important, yet
often disregarded, patients’ complaint.
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